Interestingly, both in diabetic and non-diabetic patients, the beneficial effect of SGLT2 inhibitors has been observed in heart failure, ischemic heart disease, and in chronic kidney disease: disorders which associated themselves to an activation of the sympathetic nervous system [28,29]. The gene discussed is SLC5A2; the disease is chronic kidney disease.